| 证券代码 | SPHS.O |
| 证券名称 | Sophiris Bio Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2013-08-16 |
| 首发价格(元) | 5 USD |
| 首发数量(股) | 13000000 |
| 首发募资额(元) | 65,000,000.00 USD |
| 首发主承销商 | Citigroup Global Markets Inc,Leerink Swann LLC |
| 货币单位 | USD |
| 公司名称 | Sophiris Bio Inc. |
| 注册地址 | 加拿大不列颠哥伦比亚省 |
| 办公地址 | 1258 Prospect Street, La Jolla, California, USA |
| 成立日期 | 2003-05 |
| 董事会主席 | Lars G. Ekman |
| 公司属地 | Canada 加拿大 |
| 公司网址 | www.sophirisbio.com |
| 电话 | +1 (858) 777-1760 |
| 传真 | - |
| 公司简介 | Sophiris Bio Inc. ("ophiris") is a late-stage, clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin, a first-in-class, pore-forming protein, is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations around prostate tumor cells and in the transition zone of the prostate. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). More than 400 patients have received topsalysin, which continues to appear to be safe and well tolerated. |